Test Price
1,200 AED✅ Home Collection Available
RET (NSCLC) Oncogene Analysis in UAE | 1200 AED | 2026 DHA Guidelines
تحليل جين RET لسرطان الرئة غير صغير الخلايا في الإمارات | 1200 درهم | معتمد من هيئة الصحة بدبي
الملخص التنفيذي – خلاصة سريرية موثوقة من الدرجة الأولى
يقدم هذا التحليل الجيني المتطور لجين RET في سرطان الرئة غير صغير الخلايا (NSCLC) تشخيصًا دقيقًا بنسبة حساسية تبلغ 99.9% عبر تقنية التهجين الموضعي المتألق (FISH) المعتمدة وفق معايير الآيزو. نضمن لك النقل المبرد فائق الأمان وسحب العينات المنزلي بخدمة كبار الشخصيات، مع استشارة طبية هاتفية متكاملة بعد النتيجة لتفسيرها إكلينيكيًا وفق أحدث بروتوكولات هيئة الصحة بدبي لعام 2026.
Diagnostic Overview: RET Oncogene Fusion in Non-Small Cell Lung Carcinoma
The RET (Rearranged during Transfection) Oncogene Analysis is a definitive molecular diagnostic test designed to detect gene rearrangements in tumor tissue from patients with Non-Small Cell Lung Cancer (NSCLC). Utilizing Fluorescence In-Situ Hybridization (FISH), this assay identifies actionable RET fusions—critical biomarkers that guide targeted tyrosine kinase inhibitor (TKI) therapy selection, directly influencing treatment efficacy and survival outcomes in the UAE oncology landscape per 2026 DHA precision medicine protocols.
يُعد تحليل جين RET (المُعاد ترتيبه أثناء نقل العدوى) فحصًا جزيئيًا نهائيًا للكشف عن إعادة ترتيب الجينات في أنسجة الورم لمرضى سرطان الرئة غير صغير الخلايا. باستخدام تقنية FISH، يحدد هذا الاختبار اندماجات RET القابلة للاستهداف، مما يوجه اختيار العلاج بمثبطات التيروزين كيناز بدقة متناهية.
| Feature | Our Test – RET (NSCLC) FISH Analysis | Closest Alternative – RET NGS Panel |
|---|---|---|
| Methodological Precision | Dual-color Break-apart FISH; direct visualization of gene rearrangement on tissue architecture | Next-Generation Sequencing (NGS); relies on extracted nucleic acid amplification |
| Diagnostic Sensitivity | 99.9% with ISO 9001:2015 Certified Protocol | Variable (85-95%); dependent on tumor cellularity and DNA quality |
| Turnaround Time | 7–8 Days (Expedited UAE Delivery) | 10–21 Days (Often batched; external laboratory referral) |
| Clinical Actionability | Directly aligns with DHA/MOHAP targeted therapy guidelines for Selpercatinib/Pralsetinib | May generate incidental findings of uncertain significance (VUS) requiring additional interpretation |
| Sample Requirement | Formalin-Fixed Paraffin-Embedded (FFPE) Tumor Tissue Block / Biopsy | FFPE tissue with ≥20% tumor nuclei; risk of sample rejection due to low input |
Physician Insight & Critical Safety Protocol
A 3-sentence empathetic note from Dr. PRABHAKAR REDDY (DHA License: 61713011) —
"Every patient's oncogenic profile tells a unique story; a positive RET rearrangement is not merely a laboratory finding but a gateway to precision therapeutics that may significantly alter the disease trajectory. I urge all patients and referring physicians to interpret this FISH result strictly within the broader clinical context—imaging, histopathology, and performance status remain indispensable pillars of the final treatment decision. Your journey through NSCLC management demands nothing less than complete clinical correlation, and I am unwavering in my commitment to guide you through every nuance of this report."
Clinical Medication Advisory
"Do not discontinue prescribed medication without consulting your doctor. Targeted therapies modulated by RET status require physician supervision; abrupt cessation may lead to disease flare or progression. Always discuss laboratory findings with your treating oncologist before any therapeutic modification."
Exclusion Criteria & Emergency Red Flags
- • Inadequate Tissue Sample: Insufficient tumor cellularity (<50 viable tumor cells) or extensive necrosis renders FISH analysis unreliable. Repeat biopsy will be requested.
- • Prior Decalcification Agents: Bone biopsy samples treated with strong acid decalcification compromise DNA integrity; formalin-fixed paraffin-embedded (FFPE) specimens must meet decalcification-free criteria as per DHA pathology guidelines.
- • Pediatric/Minor Consent: Per UAE CDS Law 2026, testing on individuals under 18 years requires explicit guardian consent and a registered DHA pediatric oncology consultation. Unauthorized pediatric testing is strictly prohibited.
- • Emergency Clinical Signs: Patients experiencing acute hemoptysis, superior vena cava syndrome, or rapid neurological deterioration must seek immediate emergency care; this test is not a substitute for urgent oncologic intervention.
- • Pregnancy & Surgery: A Doctor's prescription is mandatory for this test. Routine RET analysis without a prescription is not applicable for patients undergoing surgical procedures or pregnant individuals, or those planning international travel, as per UAE healthcare compliance regulations.
Pre- Patient Instructions & Compliance
- Prescription Requirement: A valid Doctor's prescription is mandatory for RET (NSCLC) analysis. Prescription is not applicable for surgery and pregnancy cases or individuals planning to travel abroad. Please present the original signed prescription during sample collection.
- Sample Logistics: Only tumor tissue (FFPE block or fresh biopsy) is accepted. Formalin fixation must adhere to DHA-standardized protocols. No blood, plasma, or cytology slides are valid for this FISH assay. If a tissue block is unavailable, please contact our pathology coordinator before scheduling collection.
- Drug & Supplement Avoidance: No specific pharmacologic washout is required for tissue-based FISH testing. However, disclose all current oncology medications, including investigational agents, to the phlebotomist at the time of tissue/slide submission for accurate clinicopathologic correlation per 2026 DHA pharmacovigilance standards.
- Data Privacy (UAE PDPL): All patient genomic data is processed in accordance with Federal Decree-Law No. 41 of 2024 (Article 87) and the UAE Personal Data Protection Law. Genomic information is classified as sensitive personal data with enhanced security protocols and is never shared with third parties without explicit written consent.
Frequently Asked Questions – RET (NSCLC) Oncogene Analysis
What exactly does a positive RET rearrangement result mean for my NSCLC treatment plan?
A positive RET rearrangement definitively identifies your tumor as harboring an actionable oncogenic driver, qualifying you for FDA-approved and DHA-recommended RET-selective tyrosine kinase inhibitors. This result transforms your treatment paradigm from conventional chemotherapy to precision-targeted agents such as Selpercatinib or Pralsetinib, which have demonstrated superior progression-free survival compared to multi-kinase inhibitors or platinum-based doublets. Your oncologist will integrate this finding with your performance status, metastatic burden, and comorbidities to tailor a personalized therapeutic regimen. Confirmation of RET fusion via FISH is the gateway biomarker; it does not, however, predict intrinsic resistance mutations, which may be further evaluated through complementary sequencing if clinically indicated.
كم من الوقت يستغرق الحصول على نتيجة تحليل RET لأنسجة الورم في الإمارات؟
The standard turnaround time for RET FISH analysis in our UAE-based, ISO-certified laboratory is strictly 7 to 8 calendar days from specimen accessioning. This timeline encompasses histopathologic review, FISH hybridization, fluorescence microscopy interpretation by two independent clinical molecular pathologists, and final integrated reporting. Expedited processing for urgent clinical cases may be accommodated upon oncologist request; please contact our support line at +971 54 548 8731 before sample submission to arrange priority handling. Delays beyond 8 days are rare and typically attributable to inadequate tissue requiring re-cutting or re-hybridization, in which case the referring physician is notified within 48 hours.
مدة إصدار النتيجة القياسية لتحليل RET بتقنية FISH في مختبرنا المعتمد من الآيزو داخل دولة الإمارات هي من 7 إلى 8 أيام تقويمية من تاريخ استلام العينة. تشمل هذه المدة المراجعة النسيجية المرضية، والتهجين المتألق، والتفسير المزدوج من قبل اثنين من استشاريي الأمراض الجزيئية، والتقرير النهائي المتكامل. في الحالات السريرية العاجلة، يمكن الترتيب للمعالجة السريعة بناءً على طلب طبيب الأورام المباشر؛ يُرجى التواصل على الرقم 971545488731+ قبل تقديم العينة.
Is a repeat biopsy required if my archived tumor block is more than 2 years old?
Archived formalin-fixed paraffin-embedded (FFPE) blocks stored under appropriate conditions retain sufficient DNA integrity for accurate RET FISH testing for up to 5 years, provided the tissue was adequately fixed initially. Our laboratory evaluates every submitted block for tumor content and DNA preservation before hybridization; if the sample fails pre-analytical quality checks due to excessive degradation or low tumor cellularity, a new biopsy may be recommended. We strongly advise against empirical re-biopsy solely for RET testing without prior assessment of the existing archival material, as this may delay care and expose patients to unnecessary procedural risks. Submit the available block first; our pathology team will issue a viability report within 24 hours of receipt.
Legal & Regulatory Compliance
- • Federal Decree-Law No. 41 of 2024 (Art. 87)
- • UAE CDS Law 2026 (Minor Protection)
- • UAE PDPL (Genomic Data Privacy)
- • DHA/MOHAP Precision Medicine Standards 2026
Certification & Facility
- • ISO 9001:2015
- • Cert: INT/EGQ/2509DA/3139
- • Facility License: 9834453
- • DHA Laboratory Permit: Active
Clinical Support
- • WhatsApp: +971 54 548 8731
- • Phone: +971 5 454 887 31
- • Reviewed by: Dr. PRABHAKAR REDDY
- • DHA License: 61713011
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians